Since its discovery, CRISPR-Cas9 has become the most promising platform for genome engineering in eukaryotic cells. Recently, the CRISPR-Cas9 system has triggered enormous interest in therapeutic applications. CRISPR-Cas9 can be applied to correct disease-causing gene mutations or can be used as a blueprint for a direct treatment approach to help establish better organismal models that more faithfully mimic human neurodegenerative diseases. There is a potential utility of CRISPR/Cas9 as a treatment option for Alzheimer’s Disease by targeting specific genes including those that cause early-onset AD, as well as those that are significant risk factors for late-onset AD.